Antibody developer XO1, backed by a Johnson & Johnson-backed fund, has been acquired by another Johnson & Johnson subsidiary, Janssen Parmaceuticals.
Janssen Pharmaceuticals, a pharmaceutical subsidiary of healthcare product manufacturer Johnson & Johnson, acquired UK-based virtual biopharmaceutical company XO1 yesterday, giving an exit to another Johnson & Johnson subsidiary.
XO1 was founded to further develop ichorcumab, an anti-thrombin antibody that would be able to mimic a hypothetical human antibody that would produce an anticoagulated state without a predisposition to bleeding.
The company leases the technology from Cambridge University Hospitals and Cambridge University, where it was originally developed. It was established and…
